via Phys.org
Antibody building blocks stuck together with bacterial superglue can protect against bunyaviruses, and herald a new approach to developing antibodies to fight emerging viruses.
Synthetic antibodies constructed using bacterial superglue can neutralise potentially lethal viruses, according to a study published last week in eLife.
The findings provide a new approach to preventing and treating infections of emerging viruses and could also potentially be used in therapeutics for other diseases.
Bunyaviruses are mainly carried by insects, such as mosquitoes, and can have devastating effects on animal and human health. The World Health Organization has included several of these viruses on the Blueprint list of pathogens likely to cause epidemics in humans in the face of absent or insufficient countermeasures.
“After vaccines, antiviral and antibody therapies are considered the most effective tools to fight emerging life-threatening virus infections,” explains author Paul Wichgers Schreur, a senior scientist of Wageningen Bioveterinary Research, The Netherlands. “Specific antibodies called VHHs have shown great promise in neutralising a respiratory virus of infants. We investigated if the same antibodies could be effective against emerging bunyaviruses.”
Antibodies naturally found in humans and most other animals are composed of four ‘chains’ – two heavy and two light. VHHs are the antigen-binding domains of heavy chain-only antibodies found in camelids and are fully functional as a single domain. This makes VHHs smaller and able to bind to pathogens in ways that human antibodies cannot. Furthermore, the single chain nature makes them perfect building blocks for the construction of multifunctional complexes.
In this study, the researchers immunised llamas with two prototypes of bunyaviruses, the Rift Valley fever virus (RVFV) and the Schmallenberg virus (SBV), to generate VHHs that target an important part of the virus’ infective machinery, the glycoprotein head. They found that RVFV and SBV VHHs recognised different regions within the glycoprotein structure.
When they tested whether the VHHs could neutralise the virus in a test tube, they found that single VHHs could not do the job. Combining two different VHHs had a slightly better neutralising effect against SBV, but this was not effective for RVFV. To address this, the team used ‘superglue’ derived from bacteria to stick multiple VHHs together as a single antibody complex. The resulting VHH antibody complexes efficiently neutralised both viruses, but only if the VHHs in the complex targeted more than one region of the virus glycoprotein head.
Studies in mice with the best performing VHH antibody complexes showed that these complexes were able to prevent death. The number of viruses in the blood of the treated mice was also substantially reduced compared with the untreated animals.
To work in humans optimally, antibodies need to have all the effector functions of natural human antibodies. To this end, the team constructed llama-human chimeric antibodies. Administering a promising chimeric antibody to mice before infection prevented lethal disease in 80% of the animals, and treating them with the antibody after infection prevented mortality in 60%.
“We’ve harnessed the beneficial characteristics of VHHs in combination with bacterial superglues to develop highly potent virus neutralising complexes,” concludes senior author Jeroen Kortekaas, Senior Scientist at Wageningen Bioveterinary Research, and Professor of the Laboratory of Virology, Wageningen University, The Netherlands. “Our approach could aid the development of therapeutics for bunyaviruses and other viral infections, as well as diseases including cancer.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Synthetic antibodies
- Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl
A research team has developed a fentanyl sensor that is six orders of magnitude more sensitive than any electrochemical sensor for the drug reported in the past five years. The portable sensor can ...
- The Future of Antibody-Drug Conjugates in Lung Cancer Treatment
Drs Jacob Sands and Benjamin P. Levy discuss antibody-drug conjugates in lung cancer treatment, including differences in efficacy, toxicity profiles, and what the future holds.
- Emerging Legal Terrain: IP Risks from AI's Role In Drug Discovery
This article explores the benefits and risks of AI-driven drug discovery from the legal perspective. Since the law governing IP rights in AI-driven drug discovery is still in its infant state, any ...
- Making the promise of monoclonal antibody therapies available to all
As Americans strive to move beyond Covid-19, it is important to acknowledge that for their 7 million immunocompromised fellow citizens the pandemic continues to be an ongoing challenge.
- Antibody Advancements: A Look into the Future of Immunodiagnostics Reagents
Another emerging trend is the development of synthetic antibodies or aptamers, which are short nucleic acid sequences selected for their ability to bind to specific targets. Aptamers offer advantages ...
Go deeper with Google Headlines on:
Synthetic antibodies
[google_news title=”” keyword=”synthetic antibodies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Virus neutralising complexes
- Breakthrough vaccine strategy guides the immune system to generate HIV neutralizing antibodies
A team led by the Duke Human Vaccine Institute (DHVI) has developed a vaccine approach that works like a GPS, guiding the immune system through the specific steps to make broadly neutralizing ...
- Best Antivirus Software for 2024
Clifford is a managing editor at CNET, where he leads How-To coverage. He spent a handful of years at Peachpit Press, editing books on everything from the first iPhone to Python. He also worked at ...
- Current Perspectives on HPV Vaccination
Thirty years ago, human papillomavirus types 16 and 18 were isolated from cervical carcinomas, and it has been almost 10 years since the introduction of the first prophylactic virus-like particle ...
- DNA vaccine against zika performs well in tests on mice
The target chosen by the researchers for the zika vaccine is the protein complex ... to a sustained neutralizing response, protecting the mice after they were exposed to the virus.
- Are We Getting Closer to the Treatment of Rabies?
To be economically viable, antivirals will need to be developed that target a number of RNA viruses and not just the rabies virus ... the impetus for a more complex, physiological approach ...
Go deeper with Google Headlines on:
Virus neutralising complexes
[google_news title=”” keyword=”virus neutralising complexes” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]